Physician profile
Jeffrey E Boatman
NPI 1265570592
$6,903.75
in general payments reported to CMS, 2019-2025
20 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,366 · 2022: $1,351 · 2023: $374 · 2024: $412 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,818.89 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Genentech USA, INC. | $750.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $647.51 | 2021-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $538.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $214.93 | 2021-2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $185.12 | 2021-2025 | Ingrezza |
| Biogen, INC. | $116.90 | 2021-2022 | |
| Abbvie INC. | $114.81 | 2024 | |
| Alkermes, INC. | $85.59 | 2022-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $75.90 | 2022-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $55.75 | 2022 | |
| Lilly USA, LLC | $54.66 | 2025 | Kisunla |
| Vanda Pharmaceuticals INC. | $51.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.56 | 2022-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $35.43 | 2024-2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $33.85 | 2022-2024 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $27.98 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.40 | 2022 | |
| Axsome Therapeutics, INC. | $20.07 | 2023 | Auvelity |
| Sun Pharmaceutical Industries INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Boatman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.